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ANALYSIS OF HIV- TYPE 1 PROTEASE AND REVERSE TRANSCRIPTASE IN BRAZILIAN CHILDREN
FAILING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)*
Daisy Maria MACHADO(1,2), Silvana Cláudia FERNANDES(1), Regina Célia de Menezes SUCCI(2), Wilton Santos FREIRE(1), Cláudio Sérgio PANNUTI(1),
Aída Barbosa GOUVEIA(2), José Eduardo LEVI(1) & Ricardo Sobie DIAZ(2)
SUMMARY
 The aim of this study was to evaluate the genotypic resistance profiles of HIV-1 in children failing highly active antiretroviral
therapy (HAART). Forty-one children (median age = 67 months) receiving HAART were submitted to genotypic testing when
virological failure was detected. cDNA was extracted from PBMCs and amplified by nested PCR for the reverse transcriptase and
protease regions of the pol gene. Drug resistance genotypes were determined from DNA sequencing. According to the genotypic
analysis, 12/36 (33.3%) and 6/36 (16.6%) children showed resistance and possible resistance, respectively, to ZDV; 5/36 (14%)
and 4/36 (11.1%), respectively, showed resistance and possible resistance to ddI; 4/36 (11.1%) showed resistance to 3TC and D4T;
and 3/36 (8.3%) showed resistance to Abacavir. A high percentage (54%) of children exhibited mutations conferring resistance to
NNRTI class drugs. Respective rates of resistance and possible resistance to PIs were: RTV (12.2%, 7.3%); APV (2.4%, 12.1%);
SQV(0%, 12.1%); IDV (14.6%, 4.9%), NFV (22%, 4.9%), LPV/RTV (2.4%, 12.1%). Overall, 37/41 (90%) children exhibited
virus with mutations related to drug resistance, while 9% exhibited resistance to all three antiretroviral drug classes.
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Abreviations used in the paper: HAART: Highly Active
Antiretroviral Therapy: ZDV: Zidovudine; 3TC: Lamivudine; D4T:
Stavudine; ABC: Abacavir; NVP: Nevirapine; EFV: Efavirenz; NFV:
Nelfinavir; RTV: Ritonavir; SQV: Saquinavir; IDV: Indinavir; LPV:
Lopinavir/RTV; APV: Amprenavir; RT: Reverse transcriptase; Pt:
Protease; NRTI: Nucleoside analogue reverse transcriptase inhibitor;
NNRTI: Non-Nucleoside analogue reverse transcriptase inhibitor; PI:
Protease inhibitor; PBMCs: Peripheral blood mononuclear cells.
INTRODUCTION
The main goal of antiretroviral therapy is to suppress HIV
replication to the greatest extent for as long as possible. Combination
drug protocols for effective viral suppression require multiple daily
doses of three or more medications over an indefinite period (HAART).
Despite some progress in antiretroviral therapy, the lack of adequate
pediatric formulations for certain drugs, together with maintaining the
treatment regimen, have created a challenging situation for pediatricians
providing treatment to infants and young children.
In Brazil, antiretroviral drugs are provided free of cost by the health
system to HIV-1 infected patients. The use of the three- drugs
combination therapy with children was begun in 1997 at our clinical
practice, and although we noted prolonged survival of the pediatric
population6,10, we encountered other serious issues such as drug
resistance. The emergence of HIV resistant strains during antiretroviral
therapy is one of the main reasons for treatment failure in HIV-infected
children3. Resistance of HIV-1 to antiretroviral agents results from
mutations within the pol gene, which encodes for the viral reverse
transcriptase (RT) and protease (Pt) regions, targets of currently used
antiretroviral agents. In the present study, we analyze the genotypic
resistance profiles of HIV in Brazilian children failing highly active
antiretroviral therapy (HAART).
METHODS
The current study was conducted at Federal University of São Paulo,
São Paulo, Brazil, between May 2000 and June 2001. The medical
record review of 160 HIV-infected children attending the outpatient
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clinic (CEADIPe) identified 63 eligible children for this study.
Eligibility requirements included: age < 18 years; current antiretroviral
treatment composed by at least 3 drugs (2 NRTIs plus 1 PI, or 2 NRTIs
plus 1 NNRTI); displaying one of the following criteria for virologic
failure16: a less than 10-fold decrease from baseline HIV RNA levels
in those receiving two NRTIs and one PI, or a less than 5-fold decrease
from baseline HIV RNA levels in those receiving two NRTIs plus one
NNRTI after 12 weeks of therapy; lack of a sustained decrease in HIV
RNA copy number of 1.5 to 2.0 log10 from baseline; repeated detection
of HIV RNA in patients who had undetectable levels prior to beginning
therapy; or a persistent increase in HIV RNA levels after beginning of
treatment greater than 3-fold in children aged two years or more, or
greater than 5-fold in children under two years of age.
Of the 63 eligible children 41 composed the study population (Table
1). Reasons for not participating included: blood sample not available
during the study period; and caregiver refusal. All children (median
age = 67 months) included had been receiving HAART (2 NRTIs plus
1 PI, or 2 NRTIs plus 1 NNRTI) for a median period of 12 months. The
caregivers of the study participants signed an informed–consent form
previously approved by the local institutional review board.
Quantification of HIV-1 RNA and T-cell subsets in peripheral
blood: HIV-1 RNA copy numbers (viral load) were measured using a
quantitative assay (NASBA, Biomérieux, France) with a lower
quantitation limit of 80 copies/ml. T-lymphocyte subsets in peripheral
blood were quantified by flow cytometry.
HIV-1 genotyping: DNA was extracted from PBMCs and amplified
by nested PCR for the reverse transcriptase (RT) and protease (Pt)
regions of the pol gene. Direct, bidirectional, dideoxynucleotide
terminator cycle sequencing of the PCR product was performed using
the OpenGene™DNA Sequencing System as described elsewhere7.
Sequences were analyzed and manually proofread and edited.
Analysis of drug-resistance mutations: Consensus guidelines for
resistance testing8 were used to define well-characterized, drug-
resistance mutations. These mutations and the drugs to which they are
related are (primary mutations are denoted by an asterisk): Ritonavir
(RTV), K20M/R, V32I, L33F, M36I, M46I/L, I54L/V, A71T/V, V77I,
V82A/F/S/T*, I84V*, and L90M*; Nelfinavir (NFV) L10I, K30N*,
M36I, M46I, G48V, A71T/V, V77I, I84V*, N88D, L90M*; Amprenavir
(APV) V32I, M46I/L, I47V, I50*, I84V* Zidovudine (ZDV), M41L,
D67N, K70R*, L210W, T215F/Y* and K219Q; Didanosine (ddI),
K65R, L74V*, and M184I/V; Stavudine (d4T), V75T; 3TC, E44D*,
V118I*, and M184*; Nevirapine (NVP), L100I, K103N*, V106A*,
V108I*, Y181C/I*, Y188C/H/L*, and G190A*; Efavirenz L100I,
K103n*, Y188C/H/L*, P236L*; and multinucleoside, Q151M, 69
insertion. Strains with genetic mixtures of mutant and wild-type
sequences at amino acid sites that code for major drug resistance were
considered to be drug-resistant.
RESULTS
Thirty three of 41 children exhibited complete sequences from both
the RT and Pt regions. Thirty-six sequences from the RT, and 38
sequences from the Pt regions were available for analysis. According
to the genotypic analysis (GuideLines TM Rules 5.0, Visible Genetics)7,
12 of 36 (33.3%) children showed resistance to ZDV, while 6 showed
possible resistance to this drug (16.6%); 5/36 (14%) and 4/36 (11.1%)
showed resistance or possible resistance, respectively, to ddI; 4/36
(11.1%) showed resistance to 3TC and D4T; and 3/36 (8.3%) showed
resistance to Abacavir. A high percentage of children exhibited
mutations conferring resistance to Nevirapine (44.4%) and Efavirenz
(38.8%) (Fig. 1). Tables 2 and 3 show mutations related to decreased
susceptibility to antiretroviral drugs and the antiretroviral therapy
history, respectively. The major mutations related to PI resistance were
D30N (n = 2), M46I (n = 3), V82A (n = 7) and L90M (n = 2),
corresponding to the following respective rates of resistance and
possible resistance to the different drugs: RTV (12.2%; 7.3%); APV
(2.4%, 12.1%); SQV (0%, 12.1%); IDV (14.6%, 4.9%), NFV (22%,
4.9%), LPV/RTV (2.4%, 12.1%) (Fig. 2).
Table 1
General characteristics of the study population at the time of genotypic testing.
VL, stands for the log10 of plasma viral load
Total of Patients (n) 41  
Median age (months) (range) 66 (12-232)
Transmission route (n)
Vertical 38
Transfusional 3
Clinical category according to CDC*  n %
A 12 29.3
B 12 29.3
C 15 36.6
N 2 4.9
Laboratory Parameters at genotyping Median Range
Log 10 viral load (copies/ml) 4.15 2.1- 6.4
   CD4 (X 10 6 cell/L) 960 52-2748
   CD8 (X 10 6 cell/L) 1469 411-7017
*CDC indicates Centers for Disease Control and Prevention
Fig. 1 - Incidence of resistance or possible resistance to NRTI and NNRTI in HIV- infected
children failing HAART. ZDV= Zidovudine; 3TC=Lamivudine; D4T=Stavudine; ABC=
Abacavir; NVP= Nevirapine; EFV= Efavirenz
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The percentages of patients with mutations related to drug resistance
varied according to the drug classes employed: 57% for NRTI, 54%
for NNRTIs, and 67% for PIs.
Three of 33 (9%) children with complete sequences from both the
protease and reverse transcriptase regions of the pol gene showed
resistance to all three drugs classes (MDR), while 4/33 (12%) children
showed no genotypic resistance at all.
By the time genotypic testing was performed, 19 children showed
a PI-based HAART, while eight (42%) showed resistance to this drug
class. Three of eleven children (27%) previously exposed to PIs and
receiving NNRTI-based HAART were resistant to at least one PI.
DISCUSSION
Our analyses of HIV-1 from samples obtained at the time of
virological failure revealed a high incidence of virus with mutations
Fig. 2 - Incidence of resistance or possible resistance to PIs in HIV infected children failing
HAART. NFV=Nelfinavir; RTV= Ritonavir; SQV= Saquinavir; IDV= Indinavir; LPV=
Lopinavir/RTV; APV= Amprenavir
Table 2
Genotypic profiles of viral isolates and antiretroviral exposure for each patient
ID Clinical stage NRTI Mutations NNRTI Mutations PI Mutations Drugs used in therapya
of patient
(CDC)
1 B2 none K103N L10V;M36I D4T/ddI/EFV,AZT
2 C3 D67N;K70R;F116Y K103N L63P;V77I D4T/ddI/EFVAZT;3TC;RTV
3 A1 L210W;T215Y Y188L M36I D4T/ddI/EFV;AZT
4 B3 M41L K103N M46I;L63P;V77I;L90M D4T/NVP/NFV;AZT;3TC;RTV
5 C3 M41L;D67N;K70R;T215Y none L10V;K70R;M36I;I54V;L63P;V82A AZT/ddI/NFV;D4T;3TC;RTV
6 B3 V179I;Y181I;G190A L10I;K20R;M36I;I54V;L63P;A71V;V82A D4T/NVP/NFV;AZT;3TC;RTV
7 B2 T215F A98G;L100I;K103N L10I;K20R;M36I;I54V;L63P;V82A D4T/ddI/EFV;AZT;3TC;RTV
8 C3 M41L;D67N;K70R L100I;K103N;V108I L24I;M36I; D4T/ddI/EFV;AZT;3TC;RTV
9 C2 none none none AZT/ddI/NFV;RTV
10 B1 M184V;T215Y A98E L63P;V77I;I93L AZT/ddI/NFV;RTV
11 C3 none none D30N;M36I;L63P;N88D AZT/ddI/EFV;D4T;3TC;NFV
12 C2 none none D30N;M36I;L63P;A71V;V77I;N88D;I93L D4T/ddI/EFV;AZT;3TC;NFV
13 C3 none none K20R;M36I;F53L;L63Q D4T/ddI/EFV
14 B3 T215Y K103N;Y188L;G190A M36I;L63P;V77I D4T/ddI/EFV;AZT
15 A1 D67N;T69N;K70R;M184V;T215F;K219Q A98G ND D4T/ddI/NFV;AZT;3TC;RTV
16 N3 M41L none L63P D4T/ddI/NVP;AZT;3TC
17 C3 none none M36I;L63S D4T/3TC/EFV;ddI;NFV
18 C3 none K103N none D4T/NFV/NVP;AZT;3TC
19 C3 M41L;L74V K101E M36I D4T/ddI/RTV;AZT;3TC;NFV
20 A2 M41L;D67N;T69D;K70R;T215Y K103N;V106A A71V;V82A D4T/ddI/NVP;AZT;3TC;NFV
21 A2 ND ND L63Q D4T/3TC/NVP;AZT;ddI
22 B2 K70R;T215Y K103N L10V AZT/ddI/EFV
23 A2 M41L;M184I;T215Y A98G M36I;I47V D4T/ddI/EFV;AZT;3TC;NFV
24 B3 ND ND M36I;L63P D4T/ddI/NVP;AZT;3TC
25 A1 M41I;D67N;T69R;V75A;T215Y K103N;V106A L63S;A71V;V77I;V82A;I93L D4T/ddI/EFV;AZT
26 A1 none none ND D4T/ddI/NFV;AZT;3TC;RTV
27 B3 M41L;D67N;T215Y none M36I;L63P;V77I;L90M D4t/ddI/NFV;AZT;3TC
28 A2 ND ND I93L D4T/ddI/NVP;AZT;3TC;NFV
29 A2 P236L K103N ND AZT/ddI/RTV; EFV;D4T;3TC
30 A2 none none L63P AZT/ddI/RTV
31 C3 M184V none M36I;I54V D4T/ddI/RTV;AZT;3TC;NFV
32 C2 ND ND M36I D4T/3TC/NFV;AZT;ddI;NVP
33 N2 K70R K103N K20R;M36I;I54V;L63P;A71V;V82A;I93L D4T/ddI/NFV;AZT;RTV
34 A1 T69N;K70R;T215Y none M36I;L63T;I93L D4T/ddI/NFV;AZT
35 B1 none none M46I;L63H AZT/ddI/RTV
36 B2 none none none D4T/ddI/NFV;AZT;3TC
37 C2 M184V K103N V77I D4T/ddI/EFV;AZT;3TC;RTV
38 C3 none none L10I;V32I;M46I;I54V;A71V;V82A D4T/ddI/EFV; AZT;NFV
39 C2 none none L63P;V77I;I93L D4T/ddI/NFV/EFV;AZT;3TC;RTV
40 A1 V118I A98G;Y181C V32I D4T/ddI/NVP;AZT;3TC
41 B2 ND ND L63P D4T/ddI/NVP;AZT;RTV
a
 Drug abbreviations: AZT, zidovudine; 3TC, lamivudine; DDI, didanosine; D4T, stavudine; NVP, nevirapine; EFV, efavirenz; RTV, ritonavir; NFV, nelfinavir. The
present regimen included the drugs listed in boldface, italic type.
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related to drug resistance (37/41; overall 90%), with percentages
varying according to specific drug classes (57% for NRTI, 54% for
NNRTIs, and 66% for PIs).
The major mutations associated with resistance to drugs not being
used when the genotyping tests were performed included those related
to Lamivudine (M184V; patient 10), or either Ritonavir or Indinavir
(V82A; patients 5, 6, 20, 25, 33) and NNRTIs (K103N; patient 33). In
some cases, these mutations may have been selected during a previous
regimen and maintained by subsequent treatments15. However, this is
unlikely to be the case for patients 10, 25 and 33, who exhibited
principal mutations related to drugs to which they had not been
previously exposed. In these three cases, a plausible explanation may
be an uncommon cross-resistance phenomenon, such as M184V
Table 3
Antiretroviral therapy history of 41 children failing HAART
Therapeutic history n Patients ID
Less than 3 prior ARV schemes 21 1, 3, 8, 9, 13, 14, 17,
20, 21, 22, 23, 24, 25,
26, 30, 31, 33, 34, 35,
40, 41
≥ 3 prior ARV schemes 20 2, 4, 5, 6, 7, 10, 11,
12, 15, 16, 18, 19, 27,
28, 29, 32, 36, 37, 38,
39
First ARV therapy
Monotherapy 8 5, 6, 10, 15, 18, 19,
21, 37
Double therapy 25 1, 2, 3, 4, 7, 11, 12,
13, 14, 16, 17, 20, 23,
24, 25, 27, 28, 29, 30,
32, 34, 36, 38, 39, 40
HAART 9 8, 9, 22, 26, 30, 31,
33, 35, 41
Time since first ARV scheme
< 2 years 13 1, 3, 9, 10, 13, 14, 17,
31, 34, 35, 38, 41
2-3 years 16 2, 8, 11, 12, 16, 20,
22, 23, 24, 25, 28, 30,
31, 33, 36, 40
> 3 years 14 4, 5, 6, 7, 15, 18, 19,
21, 26, 27, 29, 32
37, 39
Previous treatment without PI 14 2, 4, 5, 6, 7, 8, 9, 10,
11, 12, 15, 17, 19,
20, 23, 26, 28, 31,
33, 37, 38, 39, 41
Previous treatment with PI 23 1, 3, 14, 16, 18, 21,
24, 25, 27, 29, 32,
34, 36, 40
Patients receiving the first 4 13, 22, 30, 35
ARV scheme
selected by DDI in patient 10, or V82A by Nelfinavir in patient 25, or
less likely, primary resistance from mother-to-child transmitted resistant
strains, which is probably the case for K103N in patient 33.
Only four children were NRTI naive when HAART was begun and
were experiencing their first therapeutic failures when submitted to
genotypic testing (patients 13, 22, 30 and 35). Most children (90%)
had been treated with antiretroviral nucleoside RT inhibitors before
beginning of HAART. Consequently, many triple drug regimens
included one or two NRTIs already used by the children, and this may
be one of the reasons for difficulty in adequate suppression of viral
replication and the subsequent failure of ARV treatment in this
population.
Several findings in this study illustrate the consequences of
sequential, non-potent regimens, with subsequent, sub-optimal
responses to more potent schemes. Serial monotherapy with NRTIs
may have selected for thymidine-associated mutations (TAM), along
with resistance to ddI, ABC and 3TC. Conceivably by the time HAART
was begun, truly potent, antiretroviral regimen for these children could
not be developed due to cross-resistance to the “new” NRTIs. Not
surprisingly, the responses to PIs or NNRTIs were transient, with
selection of resistance mutations related to these drug classes. Our
patients were extensively treated with Didanosine and Stavudine,
although we found a low incidence of mutations at codons 74 and 75,
consistent with other published reports5,9. Although the children in this
study had never received ABC, a high percentage of resistance to this
drug (8.3%) was found, according to one of the following rules from
Guidelines rules 5.0 3: NRTI 2, NRTI 3, NRTI 22. These findings again
suggest cross-resistance.
Four children carried no resistance mutations in the context of a
rising plasma HIV-1 RNA levels. In these cases, poor adherence to the
treatment regimen should be thoroughly investigated, although cellular
resistance, and/or the low, or theoretically, occasionally low, sensitivity
of the test in detecting resistant strains (low negative predictive value)
may be the cause12.
Our results confirm the close relationship between therapeutic
failure and genotypic resistance in children, as also shown for
adults1,14,16. The present study was not designed to assess whether the
resistance found is the cause or the consequence of therapeutic failures.
However, it is important to emphasize the possible interacting roles of
adherence to the treatment regimen, regimen potency, and
pharmacokinetics that may negatively influence the effectiveness of
antiretroviral therapy in children.
Results like those shown here emphasize the importance of
considering the appropriate moment at which to initiate ARV therapy,
as well as the choice of adequate, suppressive, antiretroviral drugs.
This may be especially important in children who exhibited a naturally
high viral load compared to adults2,11. Thus, viral suppression with
less potent regimens may not be effective considering the subsequent
loss of efficacy in the succeeding regimens. The longer a child remains
on a suboptimal suppressive regimen, the greater the likelihood of
secondary mutations developing, and the greater the risk of subsequent,
cross-resistance and drug failure13.
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RESUMO
Análise da protease e transcriptase reversa do HIV-1 em
crianças com falha terapêutica em uso de terapia
anti-retroviral altamente eficaz (HAART)
O objetivo deste estudo foi avaliar o perfil de resistência genotípica
do HIV-1 em crianças com falha terapêutica ao tratamento anti-
retroviral (HAART). Quarenta e uma crianças (idade mediana = 67
meses) em uso de HAART foram submetidas ao teste de genotipagem
no momento da detecção de falha ao tratamento. Foi realizada extração
de cDNA de células periféricas mononucleares e amplificação do
mesmo (regiões da transcriptase reversa e protease do gene pol) através
de PCR-nested. O perfil genotípico foi determinado através do
seqüenciamnto de nucleotídeos. De acordo com a análise genotípica,
12/36 (33,3%) e 6/36 (16,6%) crianças apresentaram, respectivamente,
resistência e possível resistência ao AZT; 5/36 (14%) e 4/36 (11,1%),
respectivamente, eram resistentes e possivelmente resistentes ao ddI;
4/36 %11,1%) apresentaram resistência ao 3TC e D4T, e 3/36 (8,3%)
eram resistentes ao ABC. Uma alta porcentagem de crianças (54%)
apresentou mutações relacionadas à resistência aos inibidores da
trancriptase reversa não-análogos de nucleosídeos. As taxas de
resistência e possível resistência aos inibidores da protease foram,
respectivamente: RTV (12,2%; 7,3%); APV (2,4%; 12,1%); SQV (0%;
12,1%); IDV (14,6%; 4,9%); NFV (22%; 4,9%); LPV/RTV (2,4%;
12,1%). No total, 37/41 (90%) crianças apresentaram vírus com
mutações relacionadas à resistência a alguma droga, sendo que 9%
delas tinham vírus resistentes às três classes de drogas anti-retrovirais
disponíveis.
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